Brentuximab Vedotin

Mechanism

A targeted cancer therapy that combines an antibody (which finds and attaches to cancer cells) with a powerful cell-killing peptide payload. The antibody seeks out the CD30 marker on Hodgkin lymphoma cells and delivers the toxic peptide (MMAE) directly inside them — like a guided missile. This approach kills cancer cells while sparing most healthy tissue.

Effects

ONCOLOGY (HEMATOLOGIC MALIGNANCIES): Brentuximab vedotin (Adcetris) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody linked to monomethyl auristatin E (MMAE), a synthetic cytotoxic peptide/tubulin polymerization inhibitor derived from dolastatin 10 [pharmacological]. CD30 is a cell surface glycoprotein highly expressed on Hodgkin lymphoma Reed-Sternberg cells and anaplastic large cell lymphoma (ALCL) cells, with limited expression on normal tissues — making it an excellent tumor-selective target [clinical]. MECHANISM: After binding CD30, the ADC is internalized via receptor-mediated endocytosis. In the lysosome, the protease-cleavable linker (valine-citrulline) is cleaved by cathepsin B, releasing free MMAE intracellularly. MMAE binds tubulin, inhibits polymerization, causes G2/M cell cycle arrest, and induces apoptosis [in vitro, pharmacological]. The bystander effect: released MMAE can diffuse to neighboring CD30-negative tumor cells in the microenvironment, killing them too — this is important in Hodgkin lymphoma where Reed-Sternberg cells are a minority of the tumor mass [in vitro, clinical observation]. IMMUNE SYSTEM: CD30 targeting may deplete CD30+ regulatory T cells in the tumor microenvironment, potentially enhancing anti-tumor immune responses [preclinical]. Combination with checkpoint inhibitors (nivolumab) shows synergistic activity [Phase 1/2]. CLINICAL EFFICACY: In classical Hodgkin lymphoma (cHL): objective response rate 75% (34% complete response) in relapsed/refractory disease [pivotal Phase 2]. ECHELON-1 (frontline cHL): brentuximab vedotin + AVD vs. ABVD — 5-year modified PFS 82% vs. 75% (HR 0.68) — established A+AVD as new standard of care [RCT]. ECHELON-2 (frontline CD30+ peripheral T-cell lymphoma): PFS 48 months vs. 21 months with CHOP [RCT]. NERVOUS SYSTEM (ADVERSE): Peripheral neuropathy is the dose-limiting toxicity — occurs in 50-70% of patients (grade 3-4 in 10-15%). Primarily sensory (numbness, tingling, pain in hands/feet), can be motor. Onset typically after 2-3 cycles. Partially reversible with dose modification — 80% improve with dose reduction or discontinuation [clinical, registry data]. HEMATOLOGIC: Neutropenia (grade 3-4 in 15-20%), anemia, thrombocytopenia. Progressive multifocal leukoencephalopathy (PML) — rare but reported (JC virus reactivation) [post-marketing].

Practitioner Guide

ADMINISTRATION: IV infusion over 30 minutes every 3 weeks (standard single-agent dose: 1.8 mg/kg, max 180 mg). In frontline cHL (A+AVD regimen): 1.2 mg/kg on Days 1 and 15 of 28-day cycles for 6 cycles, combined with doxorubicin, vinblastine, and dacarbazine. Note: bleomycin is omitted from ABVD (no B) when using brentuximab vedotin — pulmonary toxicity risk is unacceptable in combination. DOSE MODIFICATIONS FOR NEUROPATHY: Grade 1 (paresthesia/mild): continue at full dose, monitor closely. Grade 2 (moderate, interfering with function): reduce to 1.2 mg/kg. Grade 3 (severe): hold until resolution to ≤Grade 1, then resume at 1.2 mg/kg. Grade 4 or persistent Grade 3: discontinue permanently. NEUROPATHY MANAGEMENT: Proactive monitoring — ask about numbness/tingling at each visit, perform neurological exam. Duloxetine 30-60mg/day is the best-studied pharmacological intervention for chemotherapy-induced peripheral neuropathy (CIPN). Gabapentin 300-1200mg TID or pregabalin 75-150mg BID for neuropathic pain. Occupational therapy referral for fine motor deficits. Counsel patients about fall risk. Cryotherapy (ice gloves/socks during infusion) is sometimes used to reduce CIPN, though evidence is limited for MMAE-based ADCs. INFUSION REACTIONS: Premedicate with acetaminophen, diphenhydramine, and dexamethasone if prior reaction. If anaphylaxis: discontinue permanently. MONITORING: CBC with differential before each dose (neutropenia management — G-CSF prophylaxis recommended with A+AVD regimen per ECHELON-1 protocol). LFTs periodically (hepatotoxicity reported). Peripheral neuropathy assessment at each visit. RECONSTITUTION: Add 10.5 mL sterile water to 50mg vial. Final concentration 5 mg/mL. Further dilute in NS to 0.4-1.2 mg/mL for infusion. Use within 24 hours of reconstitution. Do NOT mix with other drugs. STORAGE: Refrigerate vials (2-8°C). COST: Approximately $15,000-20,000 per infusion — significant but typically covered by insurance for approved indications. CONTRAINDICATIONS: Concomitant bleomycin (fatal pulmonary toxicity). Do not use in patients with active PML. Caution in severe hepatic impairment (reduce dose to 1.2 mg/kg — increased MMAE exposure due to reduced clearance).

Evidence

• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

  Connors JM et al.; ECHELON-1 Study Group (2018) — N Engl J Med — PMID: 29224502

  In 1334 previously untreated stage III/IV classic Hodgkin lymphoma patients, A+AVD improved 2-year modified progression-free survival vs ABVD (82.1% vs 77.2%; HR 0.77, 95% CI 0.60-0.98; P=0.04), with more neutropenia and neuropathy but less severe pulmonary toxicity.

  strong

Research Summary

TIER 1: Pivotal Phase 2 (Younes et al., 2012 — JCO): single-agent brentuximab vedotin in relapsed/refractory cHL — ORR 75%, CR 34%, median PFS 5.6 months. Led to accelerated FDA approval 2011. ECHELON-1 (Connors et al., 2018 — NEJM): frontline cHL A+AVD vs. ABVD — 2-year modified PFS 82% vs. 77% (HR 0.77), updated 5-year data HR 0.68. Changed standard of care for advanced cHL. ECHELON-2 (Horwitz et al., 2019 — Lancet): frontline CD30+ PTCL BV+CHP vs. CHOP — median PFS 48 vs. 21 months (HR 0.71). FDA-approved indications: relapsed cHL, relapsed systemic ALCL, frontline cHL (with AVD), frontline CD30+ PTCL (with CHP), primary cutaneous ALCL, CD30+ mycosis fungoides. TIER 2: Meta-analyses of ADC efficacy in lymphoma. Systematic reviews of CIPN with ADCs. Guidelines: NCCN Category 1 recommendation for multiple lymphoma indications. Reviews of CD30 biology and targeting strategies. Combination studies with nivolumab (CheckMate 205 — high response rates in multiply relapsed cHL). TIER 3: Real-world registry data (SCHOLAR-1, national cancer registries). Case series of dose modification strategies for neuropathy. Long-term survivor follow-up. Reports of unusual toxicities (pancreatitis, PML). KEY FINDINGS: Brentuximab vedotin is one of the most successful ADCs in oncology and has fundamentally changed the treatment of Hodgkin lymphoma and CD30+ T-cell lymphomas. The MMAE peptide payload is a highly effective cytotoxic warhead that has been adopted for multiple other ADCs (enfortumab vedotin, polatuzumab vedotin). Neuropathy remains the primary clinical challenge. GAPS: Optimal duration of frontline therapy debated. Role in early-stage cHL being studied. Long-term cardiac effects of A+AVD unknown. Resistance mechanisms incompletely characterized. ACTIVE TRIALS: Combinations with checkpoint inhibitors in various settings. Brentuximab vedotin in earlier lines of therapy. Novel CD30-targeted approaches. Studies of neuropathy prevention strategies.